NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Anbio Biotechnology
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026
$3.27+0.14 (+4.47%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 22.2
- Dividend yield
- –
Anbio Biotechnology revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| European Union [Member] | $5.15M | $5.62M | $4.66M | $20.30M | 59.6% | -8.3% |
| Asia Pacific [Member] | $1.52M | $509.17K | $73.40K | $3.19M | 17.6% | +198.6% |
| Other Regions [Member] | $1.41M | $472.38K | $111.05K | – | 16.3% | +198.4% |
| North America [Member] | $296.20K | $110.51K | $215.44K | $50.00K | 3.4% | +168.0% |
| South America [Member] | $269.54K | $1.48M | $1.65M | – | 3.1% | -81.7% |
From the segment and revenue-disaggregation notes of Anbio Biotechnology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.